Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

A new GLP-1 drug, orforglipron, comes in pill form and appears to be roughly as effective as injected drugs like Ozempic.

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

"Nothing we've tested before has compared to semaglutide's ability to decrease appetite and body weight ... to gain a deeper understanding of the molecular pathways it influences.

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

While people lost more weight on tirzepatide than semaglutide, it’s still a significant amount of weight, since research considers effective weight loss of more than 5% of body weight after 12 ...

“This may be more prominent with semaglutide, as it is known to decrease weight more rapidly than bupropion-naltrexone, thus inducing greater physiological stress on the body and thus potentiall ...

The study focused primarily on semaglutide formulations for diabetes (e.g., Ozempic), as data for the obesity-specific formulation Wegovy were limited. Rapid weight loss (>10% body weight in 6 ...

A 2021 study found that, on average, people lost more than 2% of their body weight in the first 4 weeks of using semaglutide. (Semaglutide is the active ingredient in Wegovy.) For example ...

Semaglutide 2.4 mg could prevent nearly 2 million ... meaning they were aged 45 years or older, had a body mass index (BMI) of at least 27 kg/m 2, and had known ASCVD without diabetes.

Another 2021 study of adults with overweight or obesity found that participants who took semaglutide lost a mean average of 14.9% of their body weight over 68 weeks. Study participants reported ...

ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical ...